Table 1.
Characteristics of the analytic cohort at baseline
| Baseline Characteristics | Overall Cohort | No Remission at 12 mo | Remission at 12 mo |
|---|---|---|---|
| Number of patients | 85 | 38 | 47 |
| Age, yr | 50 (43–61) | 54 (44–64) | 47 (42–61) |
| Male sex, n (%) | 65 (77) | 33 (87) | 32 (68) |
| Prior immunosuppression, n (%) | 22 (26) | 11 (29) | 11 (23) |
| Treatment allocation, n (%) | |||
| Rituximab | 46 (54) | 19 (50) | 27 (57) |
| Cyclosporine | 39 (46) | 19 (50) | 20 (43) |
| Albumin, g/dl | 2.4 (2.1–2.9) | 2.4 (2.0–2.9) | 2.5 (2.2–3.0) |
| Proteinuria, g/d | 9.8 (7.1–13.9) | 11.4 (8.2–14.3) | 8.9 (7–13.7) |
| Creatinine clearance, ml/min per 1.73 m2 | 80 (65–103) | 73 (51–87) | 87 (75–118) |
| PLA2R antibody level, RU/ml | 165 (59–380) | 346 (134–590) | 116 (52–186) |
| PLA2R antibody levels (categories), n (%) | |||
| 14–20 RU/ml | 2 (2) | 1 (3) | 1 (2) |
| ≥20 RU/ml | 83 (98) | 37 (97) | 46 (98) |
| Time from biopsy to baseline, mo | 4.8 (3–8.9) | 4.7 (2.9–7.9) | 4.9 (3–9.7) |
| Interstitial fibrosis/tubular atrophy, n (%) | |||
| <10% | 47 (55) | 18 (47) | 29 (62) |
| 10%–20% | 32 (38) | 17 (45) | 15 (32) |
| >20% | 6 (7) | 3 (8) | 3 (6) |
| Global glomerulosclerosis (% of glomeruli) | 0 (0–11) | 4 (0–10) | 0 (0–14) |
| Segmental glomerulosclerosis (% of glomeruli) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
Baseline values were obtained at the time of randomization before the allocation of treatment according to the MENTOR trial protocol. Data are presented as count (frequency) or median (interquartile range). MENTOR, Membranous Nephropathy Trial Of Rituximab.